Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Clin Nephrol ; 58(2): 103-10, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12227681

RESUMO

Cyclosporin is a powerful stimulator of oxidative stress signaling, leading to TGFbeta production, NO degradation, endothelial dysfunction, hypertension and post-transplant nephropathy. Carvedilol, alpha1-beta-blocker with strong antioxidant activity, may interfere with this chain of events. Therefore, we measured monocyte ecNOS, TGFbeta and heme oxygenase-1 (HO-1) mRNA level and plasma nitrite/nitrate, 3-nitrotyrosine, an estimate of peroxynitrite, and total plasma antioxidant power in kidney-transplanted patients with post-transplant hypertension, before and after treatment with carvedilol, 25 - 50 mg o.d. orally for 4 months (n = 15). The dihydropyridine calcium channel blocker nifedipine (n = 10) was used as comparator antihypertensive drug. Blood pressure fell to a similar extent with both drugs. Carvedilol increased plasma antioxidant power and HO-1 mRNA and reduced 3-nitrotyrosine and TGFbeta mRNA levels, while the same was not observed with nifedipine. Monocyte ec NOS mRNA levels and plasma nitrite/nitrate were higher in the patients than in a normotensive healthy control group and were unaffected by either treatment. In conclusion, carvedilol reduces the oxidative stress and corrects the altered cellular signaling mediated by oxidative stress in CsA-induced post-transplant hypertension. Therefore, it may prevent long-term complications, such as endothelial dysfunction, fibrogenesis and post-transplant nephropathy by decreasing NO degradation and production of TGFbeta, a key fibrogenic cytokine, and by activating HO-1 production.


Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Bloqueadores dos Canais de Cálcio/uso terapêutico , Carbazóis/uso terapêutico , Ciclosporina/efeitos adversos , Hipertensão/induzido quimicamente , Hipertensão/tratamento farmacológico , Imunossupressores/efeitos adversos , Transplante de Rim , Nifedipino/uso terapêutico , Estresse Oxidativo/efeitos dos fármacos , Propanolaminas/uso terapêutico , Fator de Crescimento Transformador beta/efeitos dos fármacos , Tirosina/análogos & derivados , Adulto , Pressão Sanguínea/efeitos dos fármacos , Carvedilol , Avaliação de Medicamentos , Feminino , Heme Oxigenase (Desciclizante)/biossíntese , Heme Oxigenase (Desciclizante)/sangue , Heme Oxigenase (Desciclizante)/efeitos dos fármacos , Heme Oxigenase-1 , Humanos , Hipertensão/metabolismo , Masculino , Proteínas de Membrana , Pessoa de Meia-Idade , Óxido Nítrico/sangue , Óxido Nítrico Sintase/sangue , Óxido Nítrico Sintase/efeitos dos fármacos , Óxido Nítrico Sintase Tipo III , Complicações Pós-Operatórias/tratamento farmacológico , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/metabolismo , RNA Mensageiro/biossíntese , RNA Mensageiro/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos , Fator de Crescimento Transformador beta/biossíntese , Fator de Crescimento Transformador beta/sangue , Resultado do Tratamento , Tirosina/biossíntese , Tirosina/sangue , Tirosina/efeitos dos fármacos
2.
Ann Ital Med Int ; 16(2): 101-5, 2001.
Artigo em Italiano | MEDLINE | ID: mdl-11688356

RESUMO

Cyclosporin-induced hypertension and endothelial dysfunction have been attributed to the effects of cyclosporin on factors controlling vasomotor tone. Endothelial nitric oxide (NO) regulates basal vasodilation, and an NO-mediated protective mechanism from cyclosporin-induced vasoconstriction has been proposed. In transplanted patients with cyclosporin-induced hypertension, we have recently demonstrated upregulation of the NO system and superoxide and free radical overproduction, which, by increasing NO metabolism, could induce hypertension, vascular remodeling and chronic rejection. In the present work, we have evaluated endothelial constitutive NO synthase (ecNOS), transforming growth factor beta and heme oxygenase-1 (protective against oxidative stress), mRNA production and plasma NO metabolites, peroxynitrite and antioxidant power in 15 kidney transplanted patients before and after 4 months of treatment with carvedilol alpha 1-beta-blocker and potent antioxidant. Our aim was to study the efficacy of the reduction of oxidative stress on complications such as endothelial dysfunction and fibrogenesis. Monocyte ecNOS and plasma NO metabolites remained higher versus those of control subjects and were unchanged by carvedilol, while antioxidant power and heme oxygenase-1 mRNA production increased. Peroxynitrite, as well as transforming growth factor beta mRNA, were reduced by carvedilol. It also normalized blood pressure. In conclusion, carvedilol reduces oxidative stress and normalizes blood pressure; ecNOS remains upregulated while mRNA for transforming growth factor beta, a key fibrogenic cytokine, is reduced by carvedilol, which seems to preserve protective mechanisms such as NO and heme oxygenase-1 against long-term complications of oxidative stress, e.g., endothelial dysfunction, fibrogenesis and chronic rejection.


Assuntos
Antioxidantes/uso terapêutico , Carbazóis/uso terapêutico , Ciclosporina/efeitos adversos , Hipertensão/induzido quimicamente , Hipertensão/tratamento farmacológico , Estresse Oxidativo/efeitos dos fármacos , Complicações Pós-Operatórias/induzido quimicamente , Complicações Pós-Operatórias/tratamento farmacológico , Propanolaminas/uso terapêutico , Adulto , Carvedilol , Feminino , Humanos , Transplante de Rim , Masculino , Pessoa de Meia-Idade
3.
Minerva Pediatr ; 65(6): 651-67, 2013 Dec.
Artigo em Italiano | MEDLINE | ID: mdl-24217634

RESUMO

At Pediatric Oncology Centers, psychological intervention and psychotherapy are generally offered to children and adolescents for supporting their adjustment to disease and treatment. The clinical practice, however, point out that cognitive and emotional symptoms, such as psychic distortions, fatigue, anxiety, irritability and depression, are sustained by biological mechanisms connected with disease and treatment and not respondent to psychological consultation and to other psychosocial resources. These manifestations could interfere with treatment or with the long-term adjustment and call for psychopharmacological treatments. Biological factors able to cause these alterations are not yet studied in depth in clinical tradition and scientific literature on the integration of psychological and psychopharmacological intervention in pediatric oncology is still poor. In this paper organic components of psychic and behavioral alterations in the course of disease are illustrated, considering the symptoms, causes and possible remedies in the light of the most recent interdisciplinary views. The main mechanism connected with oncologic treatments - chemotherapy, surgery, radiotherapy - and responsible for psycho-organic alterations in children and adolescent with cancer are also described.


Assuntos
Transtornos Mentais/etiologia , Neoplasias/complicações , Adolescente , Ansiedade/etiologia , Criança , Depressão/etiologia , Humanos , Transtornos Mentais/diagnóstico , Transtornos Mentais/terapia , Neoplasias/psicologia , Neoplasias/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA